Pertussis (Whooping Cough) - Pipeline Review, H1 2017

  • ID: 4318753
  • Drug Pipelines
  • 96 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • DBV Technologies SA
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Indian Immunologicals Ltd
  • Kaketsuken KK
  • MORE
Pertussis (Whooping Cough) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H1 2017, provides an overview of the Pertussis (Whooping Cough) (Infectious Disease) pipeline landscape.

Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pertussis (Whooping Cough) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 8, 5, 6, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 3 molecules, respectively.

Pertussis (Whooping Cough) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pertussis (Whooping Cough) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pertussis (Whooping Cough) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • DBV Technologies SA
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Indian Immunologicals Ltd
  • Kaketsuken KK
  • MORE
  1. Introduction
  2. Pertussis (Whooping Cough) - Overview
  3. Pertussis (Whooping Cough) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Pertussis (Whooping Cough) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Pertussis (Whooping Cough) - Companies Involved in Therapeutics Development
  15. Beijing Minhai Biotechnology Co Ltd
  16. Bharat Biotech International Ltd
  17. Biological E Ltd
  18. Boryung Pharmaceutical Co Ltd
  19. Daiichi Sankyo Company Ltd
  20. DBV Technologies SA
  21. GlaxoSmithKline Plc
  22. Green Cross Corp
  23. Indian Immunologicals Ltd
  24. Kaketsuken KK
  25. LG Chem, Ltd.
  26. NanoBio Corp
  27. Sanofi
  28. Sanofi Pasteur SA
  29. Serum Institute of India Ltd
  30. Shantha Biotechnics Pvt Ltd
  31. Synthetic Biologics Inc
  32. Zydus Cadila Healthcare Ltd
  33. Pertussis (Whooping Cough) - Drug Profiles
  34. (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  55. Product Description
  56. Mechanism Of Action
  57. R&D Progress
  58. (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
  59. Product Description
  60. Mechanism Of Action
  61. R&D Progress
  62. (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
  63. Product Description
  64. Mechanism Of Action
  65. R&D Progress
  66. (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
  67. Product Description
  68. Mechanism Of Action
  69. R&D Progress
  70. (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  71. Product Description
  72. Mechanism Of Action
  73. R&D Progress
  74. (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  75. Product Description
  76. Mechanism Of Action
  77. R&D Progress
  78. (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  79. Product Description
  80. Mechanism Of Action
  81. R&D Progress
  82. (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  83. Product Description
  84. Mechanism Of Action
  85. R&D Progress
  86. (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  87. Product Description
  88. Mechanism Of Action
  89. R&D Progress
  90. (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
  91. Product Description
  92. Mechanism Of Action
  93. R&D Progress
  94. (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
  95. Product Description
  96. Mechanism Of Action
  97. R&D Progress
  98. (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
  99. Product Description
  100. Mechanism Of Action
  101. R&D Progress
  102. (diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
  103. Product Description
  104. Mechanism Of Action
  105. R&D Progress
  106. (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
  107. Product Description
  108. Mechanism Of Action
  109. R&D Progress
  110. (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
  111. Product Description
  112. Mechanism Of Action
  113. R&D Progress
  114. (diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
  115. Product Description
  116. Mechanism Of Action
  117. R&D Progress
  118. (hepatitis B + pertussis) vaccine - Drug Profile
  119. Product Description
  120. Mechanism Of Action
  121. R&D Progress
  122. BK-1310 - Drug Profile
  123. Product Description
  124. Mechanism Of Action
  125. R&D Progress
  126. bladder cancer + pertussis + tuberculosis vaccine - Drug Profile
  127. Product Description
  128. Mechanism Of Action
  129. R&D Progress
  130. BVN-002 - Drug Profile
  131. Product Description
  132. Mechanism Of Action
  133. R&D Progress
  134. DTaP-IPV-HB-PRPT - Drug Profile
  135. Product Description
  136. Mechanism Of Action
  137. R&D Progress
  138. GC-3111A - Drug Profile
  139. Product Description
  140. Mechanism Of Action
  141. R&D Progress
  142. KD-370 - Drug Profile
  143. Product Description
  144. Mechanism Of Action
  145. R&D Progress
  146. LBVD - Drug Profile
  147. Product Description
  148. Mechanism Of Action
  149. R&D Progress
  150. pertussis (acellular) vaccine - Drug Profile
  151. Product Description
  152. Mechanism Of Action
  153. R&D Progress
  154. pertussis (acellular) vaccine - Drug Profile
  155. Product Description
  156. Mechanism Of Action
  157. R&D Progress
  158. pertussis (whole cell) vaccine - Drug Profile
  159. Product Description
  160. Mechanism Of Action
  161. R&D Progress
  162. pertussis [strain BPZE1] vaccine - Drug Profile
  163. Product Description
  164. Mechanism Of Action
  165. R&D Progress
  166. pertussis vaccine - Drug Profile
  167. Product Description
  168. Mechanism Of Action
  169. R&D Progress
  170. pertussis vaccine - Drug Profile
  171. Product Description
  172. Mechanism Of Action
  173. R&D Progress
  174. SYN-005 - Drug Profile
  175. Product Description
  176. Mechanism Of Action
  177. R&D Progress
  178. VN-0105 - Drug Profile
  179. Product Description
  180. Mechanism Of Action
  181. R&D Progress
  182. Pertussis (Whooping Cough) - Dormant Projects
  183. Pertussis (Whooping Cough) - Discontinued Products
  184. Pertussis (Whooping Cough) - Product Development Milestones
  185. Featured News & Press Releases
  186. Apr 19, 2017: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study
  187. Mar 30, 2017: DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination
  188. Dec 13, 2016: Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
  189. Nov 30, 2016: GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines
  190. Nov 17, 2016: DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis
  191. Sep 06, 2016: DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination
  192. Jul 27, 2016: Nanobio to Present Intranasal Pertussis Vaccine Data at the Mucosal Immunology Course & Symposium Meeting
  193. Oct 21, 2015: Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough
  194. Jun 10, 2015: Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine
  195. Apr 27, 2015: Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)
  196. Mar 02, 2015: Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID
  197. Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA
  198. Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
  199. Sep 08, 2014: Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program
  200. Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
  201. Appendix
  202. Methodology
  203. Coverage
  204. Secondary Research
  205. Primary Research
  206. Expert Panel Validation
  207. Contact Us
  208. Disclaimer
List of Tables
  1. Number of Products under Development for Pertussis (Whooping Cough), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Companies, H1 2017 (Contd..1), H1
  4. Number of Products under Development by Universities/Institutes, H1
  5. Products under Development by Companies, H1
  6. Products under Development by Companies, H1 2017 (Contd..1), H1
  7. Products under Development by Universities/Institutes, H1
  8. Number of Products by Stage and Target, H1
  9. Number of Products by Stage and Mechanism of Action, H1
  10. Number of Products by Stage and Route of Administration, H1
  11. Number of Products by Stage and Molecule Type, H1
  12. Pertussis (Whooping Cough) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1
  13. Pertussis (Whooping Cough) - Pipeline by Bharat Biotech International Ltd, H1
  14. Pertussis (Whooping Cough) - Pipeline by Biological E Ltd, H1
  15. Pertussis (Whooping Cough) - Pipeline by Boryung Pharmaceutical Co Ltd, H1
  16. Pertussis (Whooping Cough) - Pipeline by Daiichi Sankyo Company Ltd, H1
  17. Pertussis (Whooping Cough) - Pipeline by DBV Technologies SA, H1
  18. Pertussis (Whooping Cough) - Pipeline by GlaxoSmithKline Plc, H1
  19. Pertussis (Whooping Cough) - Pipeline by Green Cross Corp, H1
  20. Pertussis (Whooping Cough) - Pipeline by Indian Immunologicals Ltd, H1
  21. Pertussis (Whooping Cough) - Pipeline by Kaketsuken KK, H1
  22. Pertussis (Whooping Cough) - Pipeline by LG Chem, Ltd., H1
  23. Pertussis (Whooping Cough) - Pipeline by NanoBio Corp, H1
  24. Pertussis (Whooping Cough) - Pipeline by Sanofi, H1
  25. Pertussis (Whooping Cough) - Pipeline by Sanofi Pasteur SA, H1
  26. Pertussis (Whooping Cough) - Pipeline by Serum Institute of India Ltd, H1
  27. Pertussis (Whooping Cough) - Pipeline by Shantha Biotechnics Pvt Ltd, H1
  28. Pertussis (Whooping Cough) - Pipeline by Synthetic Biologics Inc, H1
  29. Pertussis (Whooping Cough) - Pipeline by Zydus Cadila Healthcare Ltd, H1
  30. Pertussis (Whooping Cough) - Dormant Projects, H1
  31. Pertussis (Whooping Cough) - Dormant Projects, H1 2017 (Contd..1), H1
  32. Pertussis (Whooping Cough) - Discontinued Products, H1
List of Figures
  1. Number of Products under Development for Pertussis (Whooping Cough), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Targets, H1
  5. Number of Products by Stage and Targets, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Minhai Biotechnology Co Ltd
  • Bharat Biotech International Ltd
  • Biological E Ltd
  • Boryung Pharmaceutical Co Ltd
  • Daiichi Sankyo Company Ltd
  • DBV Technologies SA
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Indian Immunologicals Ltd
  • Kaketsuken KK
  • LG Chem, Ltd.
  • NanoBio Corp
  • Sanofi
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Shantha Biotechnics Pvt Ltd
  • Synthetic Biologics Inc
  • Zydus Cadila Healthcare Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll